Specifying a GLP Six-Month Tg.rasH2 Mouse Carcinogenicity Study for a CNS-Directed Antisense Oligonucleotide: A Request-for-Proposal Framework Supporting a Postmarketing Nonclinical Commitment
Year: 2026
Type: article
Abstract: A therapy that works by lowering expression of a disease-driving protein may be givenrepeatedly for years, so the absence of a tumour signal in a small pre-approval population is notevidence that none exists. This article builds a request for proposal (RFP) for a contract researchorganization (CRO) to conduct a GLP six-month Tg.rasH2 mouse carcinogenicity study of ahypothetical intrathecally administered antisense oligonucleotide authorized for an ultra-rareprogressive neurological disease, as one element of a postmarketing nonclinical commitment thatalso includes a separate two-year rat bioassay. It sets out the weight-of-evidence rationale underICH S1A, S1B(R1), and S1C(R2), the design questions that only the vendor can answer with thesponsor's complete data package (dose, route, frequency, exposure confirmation), pathology andstatistical requirements, a 21-month schedule measured from award, a planning budget of USD900,000 to 1,400,000, and weighted selection criteria. Recommendations address data handling,confidentiality, and intellectual property.Keywords: request for proposal; carcinogenicity; Tg.rasH2; antisense oligonucleotide; ICHS1B(R1); weight of evidence; GLP; postmarketing commitment
Institution: Northeastern University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7237359190
FWCI:
Cites:
Cited by:
Related to:
